Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Short-term outcomes of keratoconus management with wavefront-guided normalization combined with CXL stabilization

Search Title by author or title

Session Details

Session Title: Keratoconus and Phakic IOLs

Session Date/Time: Monday 12/09/2016 | 16:30-18:30

Paper Time: 16:48

Venue: Hall C4

First Author: : E.Sunay TURKEY

Co Author(s): :    F. Helvacioglu   O. Kavalcioglu   T. Akin   A. Akyurt           

Abstract Details


To investigate refractive, topometric, pachymetric, and visual rehabilitation changes induced by anterior surface normalization for keratoconus by wavefront-guided excimer laser ablation in conjunction with corneal cross-linking.


VeniVidi Eye Hospital, Istanbul, Turkey


Twenty eyes of 15 keratoconic cases subjected to the procedure were studied for visual acuity, keratometry, pachymetry, and anterior surface irregularity indices by wavefront analysis system.


The mean age of the patients was 34.16 years (range 22 to 56 years) and the mean follow-up was 6.5 ± 1.5 months (range 1 to 19 months). Preoperatively, all eyes had irregular astigmatism ranging from 0.25 to 6.00 diopters (D). The means of pre and post operative RMS of high order aberrations were 1.91 ± 0.88 and 1.28 ± 0.70 (p=0.008).The means of pre and post operative uncorrected and corrected visual acuities were 0.08±0.02, 0.25 ±0.1 and 0.53 ±0.10, 0.76±0.19 Snellen lines respectively (p1=0.107, p2<0.001). No eyes lost Snellen lines of corrected distant visual acuity; 7 eyes (35%) had an increase of more than 4 lines. Trace haze developed in 1 eye.


Short term outcomes has demonstrated that the procedure is a safe and effective method to arrest keratectasia progression and to improve corneal regularity in keratoconus management.

Financial Disclosure:


Back to previous